Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propylene glycol-hydroxypropyl guar nanoemulsion is a lubricant eye drop formulation indicated for the temporary relief of burning and irritation due to dryness of the eye, commonly used in the management of dry eye disease (DED). The active ingredient, propylene glycol (0.6%), acts as a demulcent providing lubrication, while hydroxypropyl guar serves as a pH-sensitive gelling agent that cross-links with borate ions in the tear film to form a soft gel matrix. This mechanism prolongs retention time on the ocular surface and enhances lubrication. The formulation also contains dimyristoyl phosphatidyl glycerol to replenish the lipid layer of tears, further supporting ocular surface protection. Clinical studies have demonstrated significant improvement in multiple symptoms associated with dry eye disease over 28 days without new safety concerns[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propylene glycol-hydroxypropyl guar nanoemulsion.